23 / 36
Gianni L, et al. Lancet Oncol 2015
H, trastuzumab; P, pertuzumab; T, docetaxel
PFS: all arms of therapy, ITT population
4 ciclos de
pertuzumab
PFS: 86% vs 81%
|
|
23 / 36
23 / 36
Gianni L, et al. Lancet Oncol 2015
H, trastuzumab; P, pertuzumab; T, docetaxel
PFS: all arms of therapy, ITT population
4 ciclos de
pertuzumab
PFS: 86% vs 81%